Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III
Interventions: DRUG: Denosumab|DRUG: nab-Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab
Sponsor: German Breast Group
Collaborators: Amgen|Celgene Corporation